BACKGROUND: The impact of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in patients with chronic liver disease (CLD) and liver transplant (LT) recipients remains a concern. The aim of this study was to report the impact of coronavirus disease 2019 (COVID-19) infection among patients at the tertiary health care centre Centre hospitalier de l'Université de Montréal (CHUM) during the first wave of the SARS-CoV-2 pandemic. METHODS: This real-world, retrospective cohort included all patients admitted to our liver unit and/or seen as an outpatient with CLD with or without cirrhosis and/or LT recipients who tested positive to SARS-CoV-2 infection. Cases were considered positive as defined by the detection of SARS-CoV-2 by reverse-transcription polymerase chain reaction (RT-PCR) on nasopharyngeal swabs. RESULTS: Between April 1 and July 31, 2020, 5,637 were admitted to our liver unit and/or seen as outpatient. Among them, 42 were positive for SARS-CoV-2. Twenty-two patients had CLD without cirrhosis while 16 patients had cirrhosis at the time of the infection (13, 2, and 1 with Child-Pugh A, B, and C scores, respectively). Four were LT recipients. Overall, 15 of 42 patients (35.7%) were hospitalized; among them, 7 of 42 (16.7%) required respiratory support and 4 of 42 (9.5%) were transferred to the intensive care unit. Only 4 of 42 (9.5%) patients died: 2 with CLD without cirrhosis and 2 with CLD with cirrhosis. Overall survival was 90.5%. CONCLUSION: This real-world study demonstrates an unexpectedly low prevalence and low mortality in the context of SARS-CoV-2 infection among patients with CLD with or without cirrhosis and LT recipients.
BACKGROUND: The impact of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in patients with chronic liver disease (CLD) and liver transplant (LT) recipients remains a concern. The aim of this study was to report the impact of coronavirus disease 2019 (COVID-19) infection among patients at the tertiary health care centre Centre hospitalier de l'Université de Montréal (CHUM) during the first wave of the SARS-CoV-2 pandemic. METHODS: This real-world, retrospective cohort included all patients admitted to our liver unit and/or seen as an outpatient with CLD with or without cirrhosis and/or LT recipients who tested positive to SARS-CoV-2 infection. Cases were considered positive as defined by the detection of SARS-CoV-2 by reverse-transcription polymerase chain reaction (RT-PCR) on nasopharyngeal swabs. RESULTS: Between April 1 and July 31, 2020, 5,637 were admitted to our liver unit and/or seen as outpatient. Among them, 42 were positive for SARS-CoV-2. Twenty-two patients had CLD without cirrhosis while 16 patients had cirrhosis at the time of the infection (13, 2, and 1 with Child-Pugh A, B, and C scores, respectively). Four were LT recipients. Overall, 15 of 42 patients (35.7%) were hospitalized; among them, 7 of 42 (16.7%) required respiratory support and 4 of 42 (9.5%) were transferred to the intensive care unit. Only 4 of 42 (9.5%) patients died: 2 with CLD without cirrhosis and 2 with CLD with cirrhosis. Overall survival was 90.5%. CONCLUSION: This real-world study demonstrates an unexpectedly low prevalence and low mortality in the context of SARS-CoV-2 infection among patients with CLD with or without cirrhosis and LT recipients.
Authors: Jasmohan S Bajaj; Guadalupe Garcia-Tsao; Scott W Biggins; Patrick S Kamath; Florence Wong; Sara McGeorge; Jawaid Shaw; Meredith Pearson; Micheal Chew; Andrew Fagan; Randolph de la Rosa Rodriguez; Janelle Worthington; Amy Olofson; Vanessa Weir; Calvin Trisolini; Sarah Dwyer; K Rajender Reddy Journal: Gut Date: 2020-07-13 Impact factor: 23.059
Authors: Luca S Belli; Constantino Fondevila; Paolo A Cortesi; Sara Conti; Vincent Karam; Rene Adam; Audrey Coilly; Bo Goran Ericzon; Carmelo Loinaz; Valentin Cuervas-Mons; Marco Zambelli; Laura Llado; Fernando Diaz-Fontenla; Federica Invernizzi; Damiano Patrono; Francois Faitot; Sherrie Bhooori; Jacques Pirenne; Giovanni Perricone; Giulia Magini; Lluis Castells; Oliver Detry; Pablo Mart Cruchaga; Jordi Colmenero; Frederick Berrevoet; Gonzalo Rodriguez; Dirk Ysebaert; Sylvie Radenne; Herold Metselaar; Cristina Morelli; Luciano G De Carlis; Wojciech G Polak; Christophe Duvoux Journal: Gastroenterology Date: 2020-12-09 Impact factor: 22.682
Authors: Donghee Kim; Nia Adeniji; Nyann Latt; Sonal Kumar; Patricia P Bloom; Elizabeth S Aby; Ponni Perumalswami; Marina Roytman; Michael Li; Alexander S Vogel; Andreea M Catana; Kara Wegermann; Rotonya M Carr; Costica Aloman; Vincent L Chen; Atoosa Rabiee; Brett Sadowski; Veronica Nguyen; Winston Dunn; Kenneth D Chavin; Kali Zhou; Blanca Lizaola-Mayo; Akshata Moghe; José Debes; Tzu-Hao Lee; Andrea D Branch; Kathleen Viveiros; Walter Chan; David M Chascsa; Paul Kwo; Renumathy Dhanasekaran Journal: Clin Gastroenterol Hepatol Date: 2020-09-17 Impact factor: 11.382
Authors: Gwilym J Webb; Thomas Marjot; Jonathan A Cook; Costica Aloman; Matthew J Armstrong; Erica J Brenner; Maria-Andreea Catana; Tamsin Cargill; Renumathy Dhanasekaran; Ignacio García-Juárez; Hannes Hagström; James M Kennedy; Aileen Marshall; Steven Masson; Carolyn J Mercer; Ponni V Perumalswami; Isaac Ruiz; Sarang Thaker; Nneka N Ufere; Eleanor Barnes; Alfred S Barritt; Andrew M Moon Journal: Lancet Gastroenterol Hepatol Date: 2020-08-28
Authors: Thomas Marjot; Gwilym J Webb; Alfred S Barritt; Andrew M Moon; Zania Stamataki; Vincent W Wong; Eleanor Barnes Journal: Nat Rev Gastroenterol Hepatol Date: 2021-03-10 Impact factor: 73.082